June 27, 2026 10:11 am (IST)
Follow us:
facebook-white sharing button
twitter-white sharing button
instagram-white sharing button
youtube-white sharing button
Ram Mandir Trust chief Champat Rai resigns as alleged donation siphoning row escalates | Ram Mandir fund row deepens: 8 arrested days after BJP called allegations 'false narrative' | 'Who tied the hands of CBI?': Calcutta HC on RG Kar case; victim's mother, now BJP MLA, says she is 'deeply disturbed' | Construction comes to a standstill at nearly 700 Kolkata projects after Taratala warehouse tragedy kills 15 | World Cup shocker! Ecuador stun Germany 2-1, storm into Round of 32 | Iran-US conflict: Cargo vessel hit near Strait of Hormuz, UN agency pauses evacuation operations | Amazon's massive India bet! Andy Jassy announces $48 billion investment after meeting PM Modi | Taratala warehouse collapse: Death toll climbs to 8, five arrested as SIT launches probe | Oil prices crash, IndiGo takes off! Aviation and fuel stocks emerge as biggest winners | Passport is a travel document, not conclusive proof of citizenship: MEA
AstraZeneca

AstraZeneca CEO says firm found 'Winning Formula' for vaccine against COVID-19

| @indiablooms | Dec 28, 2020, at 04:12 pm

Moscow/Sputnik: AstraZeneca has found a "winning formula" to boost the efficacy of its vaccine against COVID-19, which has been developed in conjunction with the University of Oxford, CEO Pascal Soriot told the UK's Sunday Times newspaper.

The so-called Oxford vaccine had an average efficacy of 70 percent in clinical trials, although one dosing regimen, which saw participants given a half dose of the vaccine followed by a whole dose one month later, showed an efficacy rate of 90 per cent.

"We think we have figured out the winning formula and how to get efficacy that, after two doses, is up there with everybody else," Soriot told the newspaper.

The AstraZeneca CEO said that he was unable to provide full details of the optimum dosing regimen for the vaccine at this stage, adding that the results will be published at a later date.

Russia's Sputnik V vaccine against COVID-19, as well as vaccines produced by Pfizer/BioNTech and Moderna, have shown efficacy levels in excess of 90 percent during clinical trials.

The UK government has submitted purchase orders for 100 million doses of the Oxford vaccine against COVID-19. Plans are in the works for the vaccine to be rolled out to the public from January 4, the Sunday Telegraph newspaper reported earlier in the day.

Support Our Journalism

We cannot do without you.. your contribution supports unbiased journalism

IBNS is not driven by any ism- not wokeism, not racism, not skewed secularism, not hyper right-wing or left liberal ideals, nor by any hardline religious beliefs or hyper nationalism. We want to serve you good old objective news, as they are. We do not judge or preach. We let people decide for themselves. We only try to present factual and well-sourced news.

Support objective journalism for a small contribution.